계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
ABclonal
company
About
ABclonal is a biotechnology company that is a supplier of global antibody and molecular enzyme reagents.
- 251 - 500
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- ¥1.20B
- Industries
- Biometrics,Biopharma,Biotechnology
- Founded date
- Jan 1, 2011
- Number Of Employee
- 251 - 500
- Operating Status
- Active
ABclonal Technology is a rapidly growing life science research and diagnostic reagents provider. With scientists from world-class universities, the company thrives on improving the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS library preparation kits and molecular enzymes.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
¥1.20B $93M
ABclonal has raised a total of
¥1.20B $93M
in funding over 2 rounds. Their latest funding was raised on
Dec 8, 2021 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 8, 2021 | Series D | ¥1.20B | 2 | — | — | Detail |
| Feb 22, 2021 | Series C | $93M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
4
ABclonal is funded by 4 investors.
Taikang Touzi
and Zhengxingu Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series D |
|
|
— | Series D |
|
|
— | Series C |
Sigma Square Capital
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
